WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/063250    International Application No.:    PCT/JP2004/019199
Publication Date: 14.07.2005 International Filing Date: 22.12.2004
Chapter 2 Demand Filed:    26.05.2005    
A61K 31/501 (2006.01), C07D 401/12 (2006.01)
Applicants: NISSAN CHEMICAL INDUSTRIES, LTD. [JP/JP]; 7-1, Kanda-Nishiki-cho 3-chome Chiyoda-ku, Tokyo 1010054 (JP) (For All Designated States Except US).
TAISHO PHARMACEUTICAL CO., LTD. [JP/JP]; 24-1, Takada 3-chome Toshima-ku, Tokyo 1708633 (JP) (For All Designated States Except US).
IWAMA, Takehisa [JP/JP]; (JP) (For US Only).
TSURUZOE, Nobutomo [JP/JP]; (JP) (For US Only)
Inventors: IWAMA, Takehisa; (JP).
TSURUZOE, Nobutomo; (JP)
Agent: SENMYO, Kenji; Torimoto Kogyo Bldg. 38, Kanda-Higashimatsushitacho Chiyoda-ku, Tokyo 1010042 (JP)
Priority Data:
2003-433747 26.12.2003 JP
(JA) 好中球増多抑制剤
Abstract: front page image
(EN)A neutrophilia inhibitor effective in treatments for the incidence or progress of acute infectious diseases, collagen disease, chronic obstructive pulmonary disease (COPD), chronic bronchitis, pulmonary emphysema, small airway diseases, gout, Cushing syndrome, myelofibrosis, tumorous neutrophilia, polycythemia vera, and pathological states observed in, e.g., steroid agent administration. The neutrophilia inhibitor contains a 3(2H)-pyridazinone compound represented by the formula (I) or a pharmacologically acceptable salt thereof. [In the formula, R1, R2, and R3 each independently represents hydrogen or C1-6 alkyl; X represents halogeno, cyano, or hydrogen; Y represents halogeno, trifluoromethyl, or hydrogen; and A represents optionally hydroxylated C1-8 alkylene.]
(FR)La présente invention concerne un inhibiteur de neutrophilie permettant de traiter efficacement la fréquence ou la progression de maladies infectieuses aiguës, de maladies du collagène, de la broncho-pneumopathie chronique obstructive (BPCO), de la bronchite chronique, de l'emphysème pulmonaire, des maladies des petites voies respiratoires, de la goutte, du syndrome de Cushing, de la myélofibrose, de la neutrophilie tumorale, de la polycythémie vraie, et des états pathologiques observés, par exemple, lors de l'administration d'agents stéroïdes. Cet inhibiteur de neutrophilie contient un composé de 3(2H)-pyridazinone représenté par la formule (I) ou un sel pharmacologiquement acceptable de ce composé. [Dans cette formule, R<sp>1</sp>, R<sp>2</sp> et R<sp>3</sp> représentent chacun indépendamment hydrogène ou alkyle C<sb>1-6</sb>; X représente halogéno, cyano, ou hydrogène; Y représente halogéno, trifluorométhyle ou hydrogène; et A représente éventuellement alkylène C<sb>1-8</sb> hydroxylé.]
(JA)not available
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)